← ASM International NV overview

ASM International NV vs Axcelis: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

ASM International NV (ASM.AS)

Q3 2026
▼3

China chip tool breakthrough and AI slowdown fears hit ASM

  • China's own chipmaking tools threaten demand China began mass-producing its own deep ultraviolet chipmaking equipment, the machines that make advanced chips. If Chinese chipmakers buy local tools instead of Western ones, they need less of ASM's deposition equipment, so investors sold the stock hard.

    This is the biggest new force behind the drop, directly hitting ASM's future sales.

  • AI leaders call for slower development Top AI figures including Anthropic's Dario Amodei and OpenAI's Sam Altman urged a slower pace of AI development. That clouds the outlook for AI-driven chip equipment demand, and ASM fell 8.7% as investors questioned how fast AI spending will keep growing.

    A fresh, separate worry about ASM's end-market demand that drove a sharp sell-off.

  • Sector-wide tech sell-off drags ASM down Even with a positive earnings outlook, ASM dropped 4.8% as European tech stocks fell for a third straight day. When the whole sector is sold, strong company news is not enough to hold the share price up.

    Shows ASM's price is being pulled by broad sector weakness, not just its own results.

August 2026
▼3

China chip tool breakthrough and AI slowdown fears hit ASM

  • China's own chipmaking tools threaten demand China began mass-producing its own deep ultraviolet chipmaking equipment, the machines that make advanced chips. If Chinese chipmakers buy local tools instead of Western ones, they need less of ASM's deposition equipment, so investors sold the stock hard.

    This is the biggest new force behind the drop, directly hitting ASM's future sales.

  • AI leaders call for slower development Top AI figures including Anthropic's Dario Amodei and OpenAI's Sam Altman urged a slower pace of AI development. That clouds the outlook for AI-driven chip equipment demand, and ASM fell 8.7% as investors questioned how fast AI spending will keep growing.

    A fresh, separate worry about ASM's end-market demand that drove a sharp sell-off.

  • Sector-wide tech sell-off drags ASM down Even with a positive earnings outlook, ASM dropped 4.8% as European tech stocks fell for a third straight day. When the whole sector is sold, strong company news is not enough to hold the share price up.

    Shows ASM's price is being pulled by broad sector weakness, not just its own results.

Latest
▼3

China chip tool breakthrough and AI slowdown fears hit ASM

  • China's own chipmaking tools threaten demand China began mass-producing its own deep ultraviolet chipmaking equipment, the machines that make advanced chips. If Chinese chipmakers buy local tools instead of Western ones, they need less of ASM's deposition equipment, so investors sold the stock hard.

    This is the biggest new force behind the drop, directly hitting ASM's future sales.

  • AI leaders call for slower development Top AI figures including Anthropic's Dario Amodei and OpenAI's Sam Altman urged a slower pace of AI development. That clouds the outlook for AI-driven chip equipment demand, and ASM fell 8.7% as investors questioned how fast AI spending will keep growing.

    A fresh, separate worry about ASM's end-market demand that drove a sharp sell-off.

  • Sector-wide tech sell-off drags ASM down Even with a positive earnings outlook, ASM dropped 4.8% as European tech stocks fell for a third straight day. When the whole sector is sold, strong company news is not enough to hold the share price up.

    Shows ASM's price is being pulled by broad sector weakness, not just its own results.

Axcelis Technologies Inc (ACLS)

Q3 2026
▲3

Axcelis Beats Q2, Raises 2026 Outlook, Expands Korea Capacity

  • Q2 Beat and Raised 2026 Revenue Outlook Axcelis reported Q2 revenue of $215.2 million and EPS of $1.06, both above its own forecasts, and raised full-year 2026 revenue growth to mid-single digits from flat. This directly lifts profit expectations and supports a higher stock price.

    The earnings beat and guidance raise are the core new fundamental catalyst for ACLS this period.

  • $35M Korea Plant Expands Capacity in Key Region Axcelis will invest $35 million in a new ion implantation factory in Pyeongtaek, Korea, its second-largest revenue region. The plant adds capacity and shows commitment to rising semiconductor demand, though output starts only in late 2028, so near-term earnings impact is limited.

    This is a concrete new investment that signals growth and capacity expansion, a positive for long-term demand.

  • Growth Outlook Solid but Margins Under Pressure Management expects mid-single-digit 2026 revenue growth and further growth in 2027, driven by memory, power, and aftermarket demand. However, gross margin fell to 42.7% from 45.2% and operating margin dropped to 14.7% from 17.7%, a real counterweight to the positive revenue story.

    It gives the balanced picture: revenue growth is positive, but margin decline is a negative that could cap price gains.

  • Veeco Merger Nears Final China Approval The pending all-stock merger with Veeco has all regulatory clearances except China antitrust approval and remains on track to close in the second half of 2026. Progress reduces uncertainty and supports the stock, though the deal is not yet complete.

    Merger progress is a key overhang being resolved, directly affecting ACLS's price and strategic future.

September 2026
▲3

Axcelis Beats Q2, Raises 2026 Outlook, Expands Korea Capacity

  • Q2 Beat and Raised 2026 Revenue Outlook Axcelis reported Q2 revenue of $215.2 million and EPS of $1.06, both above its own forecasts, and raised full-year 2026 revenue growth to mid-single digits from flat. This directly lifts profit expectations and supports a higher stock price.

    The earnings beat and guidance raise are the core new fundamental catalyst for ACLS this period.

  • $35M Korea Plant Expands Capacity in Key Region Axcelis will invest $35 million in a new ion implantation factory in Pyeongtaek, Korea, its second-largest revenue region. The plant adds capacity and shows commitment to rising semiconductor demand, though output starts only in late 2028, so near-term earnings impact is limited.

    This is a concrete new investment that signals growth and capacity expansion, a positive for long-term demand.

  • Growth Outlook Solid but Margins Under Pressure Management expects mid-single-digit 2026 revenue growth and further growth in 2027, driven by memory, power, and aftermarket demand. However, gross margin fell to 42.7% from 45.2% and operating margin dropped to 14.7% from 17.7%, a real counterweight to the positive revenue story.

    It gives the balanced picture: revenue growth is positive, but margin decline is a negative that could cap price gains.

  • Veeco Merger Nears Final China Approval The pending all-stock merger with Veeco has all regulatory clearances except China antitrust approval and remains on track to close in the second half of 2026. Progress reduces uncertainty and supports the stock, though the deal is not yet complete.

    Merger progress is a key overhang being resolved, directly affecting ACLS's price and strategic future.

Latest
▲3

Axcelis Beats Q2, Raises 2026 Outlook, Expands Korea Capacity

  • Q2 Beat and Raised 2026 Revenue Outlook Axcelis reported Q2 revenue of $215.2 million and EPS of $1.06, both above its own forecasts, and raised full-year 2026 revenue growth to mid-single digits from flat. This directly lifts profit expectations and supports a higher stock price.

    The earnings beat and guidance raise are the core new fundamental catalyst for ACLS this period.

  • $35M Korea Plant Expands Capacity in Key Region Axcelis will invest $35 million in a new ion implantation factory in Pyeongtaek, Korea, its second-largest revenue region. The plant adds capacity and shows commitment to rising semiconductor demand, though output starts only in late 2028, so near-term earnings impact is limited.

    This is a concrete new investment that signals growth and capacity expansion, a positive for long-term demand.

  • Growth Outlook Solid but Margins Under Pressure Management expects mid-single-digit 2026 revenue growth and further growth in 2027, driven by memory, power, and aftermarket demand. However, gross margin fell to 42.7% from 45.2% and operating margin dropped to 14.7% from 17.7%, a real counterweight to the positive revenue story.

    It gives the balanced picture: revenue growth is positive, but margin decline is a negative that could cap price gains.

  • Veeco Merger Nears Final China Approval The pending all-stock merger with Veeco has all regulatory clearances except China antitrust approval and remains on track to close in the second half of 2026. Progress reduces uncertainty and supports the stock, though the deal is not yet complete.

    Merger progress is a key overhang being resolved, directly affecting ACLS's price and strategic future.